List view / Grid view
NICE has recommended olaparib tablets (Lynparza, AstraZeneca) for adults with relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer with a BRCA1 or BRCA2 mutation.
Following guidance from the drugs advisory body NICE, two cannabis-based medications have been approved for treatment by the NHS in England.
NICE in the UK and its counterpart - the Canadian Agency for Drugs and Technology in Health have collaborated to offer parallel scientific advice...
A CAR-T immunotherapy for adults with an aggressive form of non-Hodgkin lymphoma has been provisionally rejected by the NHS...
The National Institute for Health and Care Excellence (NICE) in England has recommended Teva Pharmaceutical Industries Ltd’s Cinqaero (reslizumab) in its Final Appraisal Determination (FAD).
20 May 2016 | By Katie Sadler
NICE has announced it will not be recommending pertuzumab to treat HER2-positive breast cancer because it is uncertain of the long term benefits for patients.
The National Institute for Health and Care Excellence (NICE) has issued draft guidance which does not recommend Vertex Pharmaceuticals’ Orkambi (lumacaftor-ivacaftor) for treating cystic fibrosis.
3 July 2015 | By Sir Andrew Dillon, Chief Executive, National Institute for Health and Care Excellence
Without constantly examining the systems that underpin what we as an organisation do, opportunities will be missed and performance will stagnate...
2 March 2015 | By Photocure ASA
Photocure ASA, a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, is pleased to announce that the National Institute for Health and Care Excellence (NICE) in the UK has published its first guidelines on bladder cancer, recommending photodynamic diagnosis for improved detection of bladder cancer...
2 December 2014 | By Roche
Victory for patients as NICE accepts Gazyvaro™ (obinutuzumab) for treatment of most common adult leukaemia1...
11 October 2012 | By Boehringer Ingelheim
Final guidance issued on the use of alteplase...
19 March 2012 | By NICE
Pradaxa® must now be made available for use by the UK National Health Service (NHS)...
